Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ketamine analogs

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: CYBIN

            Deal Size: $15.7 million Upfront Cash: Undisclosed

            Deal Type: Acquisition December 07, 2020


            Adelia’s leadership team brings deep clinical and commercialization experience, including past commercial success in psychedelics through the development of proprietary ketamine analogs as well as strong understanding of the underlying science.